Citations

Mayo Clinic

Showing 10 of 108585 citations.

Case 33-2023: An 86-Year-Old Man with Shortness of Breath
Chung, Ryan , Schmidt, Ada C. Stefanescu , Clark, Jeffrey W. , Pearson, Daniel S. , Luis, Sushil Allen , Stefanescu Schmidt, Ada C

New England Journal of Medicine | October 25, 2023 | Volume: 389 | Issue: 17 | Pages: 1602-1613

10.1056/nejmcpc2300908 | PMID 37888920 Get It

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS
Sakemura, Reona , Roman, Claudia Manriquez , Horvei, Paulina , Siegler, Elizabeth L. , Girsch, James H. , Sirpilla, Olivia , Stewart, Carli M. , Yun, Kun , Can, İsmail , Ogbodo, Ekene J. , Fonkoua, Lionel Aurelien Kankeu , Ruff, Michael W. , Kimball, Brooke , Long, Kirsten Hall , Huynh, Truc , Nevala, Wendy K. , Ilieva, Kristina M. , Patra-Kneuer, Maria , Schanzer, Jürgen, Endell, Jan , Heitmüller, Christina, Nowakowski, Grzegorz S. , Sakemura, R Leo , Manriquez Roman, Claudia , Sirpilla, Olivia L , Adada, Mohamad M , Bezerra, Evandro D , Fonkoua, Lionel Aurelien A Kankeu , Kimball, Brooke L , Mai, Long K , Huynh, Truc N , Ilieva, Kristina , Augsberger, Christian , Patra-Kneuer, Maria , Steidl, Stefan , Parikh, Sameer A , Ding, Wei , Kay, Neil E , Kenderian, Saad Sirop , Siegler, Elizabeth L , Can, Ismail , Stewart, Carli , Bezerra, Evandro D. , Hefazi, Mehrdad , Parikh, Sameer A. , Ding, Wei , Kay, Neil E. , Kenderian, Saad S.

Blood | October 25, 2023 | Volume: 143 | Issue: 3 | Pages: 258-271

10.1182/blood.2022018905 | PMID 37879074 Get It

Abstract In the development of various strategies of anti-CD19 immunotherapy for the treatment of B-cell malignancies, it remains unclear whether CD19 monoclonal antibody therapy impairs subsequent CD19-targeted chimeric antigen receptor T-cell (CART19) therapy. We evaluated the potential interference between the CD19-targeting monoclonal antibody tafasitamab and CART19 treatment in preclinical models. Concomitant treatment with tafasitamab and CART19 showed major CD19 binding competition, which led to CART19 functional impairment. However, when CD19+ cell lines were pretreated with tafasitamab overnight and the unbound antibody was subsequently removed from the culture, CART19 function was not affected. In preclinical in vivo models, tafasitamab pretreatment demonstrated reduced incidence and severity of cytokine release syndrome and exhibited superior antitumor effects and overall survival compared with CART19 alone. This was associated with transient CD19 occupancy with tafasitamab, which in turn resulted in the inhibition of CART19 overactivation, leading to diminished CAR T apoptosis and pyroptosis of tumor cells.
Strategies for Data Ethics Governance: Elevating Patient and Community Perspectives
Stroud, Austin M. , Wise, Journey L. , Curtis, Susan , McGowan, Michelle L. , Curtis, Susan H

The American Journal of Bioethics | October 25, 2023 | Volume: 23 | Issue: 11 | Pages: 48-50

10.1080/15265161.2023.2256277 | PMID 37879006 Get It

Diffuse hemispheric glioma with H3-3B G34R mutation: Expanding the spectrum of histone H3 genes in diffuse hemispheric glioma, H3 G34-mutant
Nazem, Amir , Lavezo, Jonathan , Abdullaev, Zied , Aldape, Kenneth , Quezado, Martha , Cimino, Patrick J. , Jenkins, Robert B. , Ida, Cristiane M. , Jenkins, RB , Ida, Cristiane M , Cimino, Patrick J , Pratt, Drew

Journal of Neuropathology & Experimental Neurology | October 25, 2023 | Volume: 83 | Issue: 1 | Pages: 58-60

10.1093/jnen/nlad089 | PMID 37878797 Get It

Effect of residual platelets in frozen-thawed plasma on results of dilute Russell’s viper venom time assay for lupus anticoagulant testing
Strande, Brenda J Nelson, Leger, Rachel, Stuart, Melissa S, Tange, Julie I, Navitska, Serena D, Heikal, Nahla, Ashrani, Aneel A. , Chen, Dong , Seheult, Jansen N. , Pruthi, Rajiv K. , Leger, Rachel R, Chen, Dong , Seheult, Jansen N , Sridharan, Meera

American Journal of Clinical Pathology | October 25, 2023 | Volume: 161 | Issue: 3 | Pages: 212-215

10.1093/ajcp/aqad138 | PMID 37878771 Get It

Abstract Objectives To determine the impact of residual platelets on dilute Russell’s viper venom time (DRVVT) assay in frozen-thawed plasma submitted for lupus anticoagulant (LAC) testing. Methods We measured platelet counts in frozen-thawed samples submitted for LAC testing and evaluated the association between platelet count and the DRVVT screening time and ratios. We also spiked platelets into a LAC-positive sample to observe the effect on the DRVVT. Results Progressive increase in platelet count resulted in a statistically significant shortening of the DRVVT assay results on plasma after 1 freeze-thaw cycle. A similar effect was noted on the LAC-positive sample. Conclusions Residual platelets in plasma samples result in shortening of DRVVT assay after 1 freeze-thaw cycle. This may result in a false-negative LAC test result.
Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival
Lipsyc-Sharf, Marla , Campbell, Jordan D., Muss, Hyman B. , Perez, Edith A. , Carey, Lisa A. , Carey, Lisa A , Ballman, Karla V. , Shulman, Lawrence N. , Partridge, Ann H. , Warner, Erica T.

JAMA Network Open | October 25, 2023 | Volume: 6 | Issue: 10 | Pages: e2339584

10.1001/jamanetworkopen.2023.39584 | PMID 37878313 Get It

ImportanceBlack women in the United States have higher breast cancer (BC) mortality rates than White women. The combined role of multiple factors, including body mass index (BMI), age, and tumor subtype, remains unclear.ObjectiveTo assess the association of race and ethnicity with survival among clinical trial participants with early-stage BC (eBC) according to tumor subtype, age, and BMI.Design, Setting, and ParticipantsThis cohort study analyzed survival data, as of November 12, 2021, from participants enrolled between 1997 and 2010 in 4 randomized adjuvant chemotherapy trials: Cancer and Leukemia Group B (CALGB) 9741, 49907, and 40101 as well as North Central Cancer Treatment Group (NCCTG) N9831, legacy groups of the Alliance of Clinical Trials in Oncology. Median follow-up was 9.8 years.ExposuresNon-Hispanic Black and Hispanic participants were compared with non-Hispanic White participants within subgroups of subtype (hormone receptor positive [HR+]/ERBB2[formerlyHER2] negative [ERBB2−],ERBB2+, and HR−/ERBB2−), age (<50, 50 to <65, and ≥65 years), and BMI (<18.5, 18.5 to <25.0, 25.0 to <30.0, and ≥30.0).Main Outcomes and MeasuresRecurrence-free survival (RFS) and overall survival (OS).ResultsOf 9479 participants, 436 (4.4%) were Hispanic, 871 (8.8%) non-Hispanic Black, and 7889 (79.5%) non-Hispanic White. The median (range) age was 52 (19.0-89.7) years. Among participants with HR+/ERBB2− tumors, non-Hispanic Black individuals had worse RFS (hazard ratio [HR], 1.49; 95% CI, 1.04-2.12; 5-year RFS, 88.5% vs 93.2%) than non-Hispanic White individuals, although the global test for association of race and ethnicity with RFS was not significant within any tumor subtype. There were no OS differences by race and ethnicity in any subtype. Race and ethnicity were associated with OS in young participants (age <50 years; globalP = .008); young non-Hispanic Black participants (HR, 1.34; 95% CI, 1.04-1.71; 5-year OS, 86.6% vs 92.0%) and Hispanic participants (HR, 1.62; 95% CI, 1.16-2.29; 5-year OS, 86.2% vs 92.0%) had worse OS than young non-Hispanic White participants. Race and ethnicity were associated with RFS in participants with BMIs of 25 to less than 30, with Hispanic participants having worse RFS (HR, 1.81; 95% CI, 1.23-2.68; 5-year RFS, 83.2% vs 87.3%) than non-Hispanic White participants.Conclusions and RelevanceIn this cohort study, racial and ethnic survival disparities were identified in patients with eBC receiving standardized initial care, and potentially at-risk subgroups, for whom focused interventions may improve outcomes, were found.
Defining the Standard for Surgical Video Deidentification
Tollefson, Matthew K. , Ross, Christopher J.

JAMA Surgery | October 25, 2023 | Volume: 159 | Issue: 1 | Pages: 104

10.1001/jamasurg.2023.1800 | PMID 37878296 Get It

This article reviews the implementation of standards for surgical video deidentification.
Microvascular cardiac amyloidosis–Cardiac involvement of amyloidosis presenting as typical chest pain
Gertz, Morie A. , Vaxman, Iuliana , Gertz, Morie A , Vaxman, Iuliana , Kaufman, Caroline, Lerman, Amir

American Journal of Hematology | October 25, 2023 | Volume: 98 | Issue: 12 | Pages: 1963-1966

10.1002/ajh.27122 | PMID 37878285 Get It

Muscle fiber phenotype: a culprit of abnormal metabolism and function in skeletal muscle of humans with obesity
Serrano, Nathan , Hyatt, Jon‐Philippe K. , Houmard, Joseph A. , Murgia, Marta , Katsanos, Christos S. , Katsanos, Christos S

American Journal of Physiology-Endocrinology and Metabolism | October 25, 2023 | Volume: 325 | Issue: 6 | Pages: E723-E733

10.1152/ajpendo.00190.2023 | PMID 37877797 Get It

The proportion of the different types of fibers in a given skeletal muscle contributes to its overall metabolic and functional characteristics. Greater proportion of type I muscle fibers is associated with favorable oxidative metabolism and function of the muscle. Humans with obesity have a lower proportion of type I muscle fibers. We discuss how lower proportion of type I fibers in skeletal muscle of humans with obesity may explain metabolic and functional abnormalities reported in these individuals. These include lower muscle glucose disposal rate, mitochondrial content, protein synthesis, and quality/contractile function, as well as increased risk for heart disease, lower levels of physical activity, and propensity for weight gain/resistance to weight loss. We delineate future research directions and the need to examine hybrid muscle fiber populations, which are indicative of a transitory state of fiber phenotype within skeletal muscle. We also describe methodologies for precisely characterizing muscle fibers and gene expression at the single muscle fiber level to enhance our understanding of the regulation of muscle fiber phenotype in obesity. By contextualizing research in the field of muscle fiber type in obesity, we lay a foundation for future advancements and pave the way for translation of this knowledge to address impaired metabolism and function in obesity.